Form 4: Doximity Director Sells Shares Following Option Exercise Under Pre-Arranged Trading Plan

Doximity, Inc. Director Kira Scherer Wampler sold 2,000 shares of Class A Common Stock for $52.89 per share after converting Class B shares, as part of a Rule 10b5-1 trading plan.

Summary

• Kira Scherer Wampler, a Director at Doximity, Inc. (DOCS), reported transactions on June 2, 2025.
• She exercised stock options to acquire 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share.
• Concurrently, 2,000 shares of Class B Common Stock were converted into 2,000 shares of Class A Common Stock.
• Following the conversion, 2,000 shares of Class A Common Stock were sold at a price of $52.89 per share.
• These transactions were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Ms. Wampler on November 12, 2024.
• After these transactions, Ms. Wampler directly beneficially owns 16,618 shares of Class A Common Stock and 474,700 stock options (right to buy Class B Common Stock).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can be perceived negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates concerns about the insider reacting to negative news. The exercise of options also indicates the realization of value.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new negative information.
• The exercise of stock options suggests the director is realizing value from previously granted equity compensation.

Negatives

• An insider sale, even if planned, reduces the director's direct equity stake in the company.

Risks

• Market perception of insider selling, which could be interpreted negatively by some investors, although mitigated by the 10b5-1 plan.

Future Outlook

The document, a Form 4, reports insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2024.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. Doximity operates in the healthcare technology sector, providing a digital platform for medical professionals.

Comparison to Industry Standards

• This document reports an individual insider transaction and does not contain information suitable for comparison to global industry benchmarks, specific comparable companies, projects, or results.

Corporate Governance

Stakeholder Impact

• Shareholders: May note the director's sale of shares, though the pre-arranged 10b5-1 plan suggests a planned liquidity event rather than a reaction to new company-specific information.

Next Steps

• The document does not specify any future actions, events, or milestones for the company or the reporting person beyond the execution of the existing 10b5-1 plan.

Key Dates

Recommendation

Keywords

Doximity, DOCS, Form 4, Insider Trading, Stock Sale, Option Exercise, Rule 10b5-1, Director, Healthcare Technology, Medical Social Network